Beijing Taiyang Pharmaceutical Industry Company Limited was founded in 1992. The Chinese partner is BEIJING SHUANGQIAO PHARMACEUTICAL CORPORATION, while the foreign partner is Sun Pharmaceutical Holding CO., LTD. It is invested by China International Capital Corp., Ltd., Government of Singapore Investment Corporation, Dutch National Investment Bank, Mingly Co., Ltd of Hong Kong and Morgan Stanley with income of CNY 200 million, increasingly by 35% each year, so it has been one of core pharmaceutical enterprises in Beijing. It was appraised to be the excellent enterprise of National Pharmaceutical Industry System from national authority in 1998, and one of 190 important large or medium sized Beijing one core enterprises in 1999.
Taiyang Pharm. possesses R&D and producing system. Its medicine researching academe is a city level enterprise technology center confirmed by Beijing Economy Committee. Its altitudinal automatic workshop passed the national-GMP authentication. The strict Qual
Year of Establishment:
1992
Total Assets(USD):
9,000,000 to 9,999,999
Total Number of Staff:
more than 500
Main Competitive Advantages:
Other Competitive Advantages:
GMP Certified;
US FDA Certified in Feb, 2009;
DMF/EDMF/COS.
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Annual Turnover(USD):
45,000,000 to 49,999,999
Main Sales Markets:
North America,Central/South America,Western Europe,Asia,Africa
Other Competitive Advantages:
GMP Certified;
US FDA Certified in Feb, 2009;
DMF/EDMF/COS.
Patents and Copyrights:
Twelve years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
